November 2026 biotech catalysts

Name: Bio Catalyst Calendar — source-anchored biotech/pharma catalyst dates
Creator: Bio Catalyst Calendar
License: https://www.usa.gov/government-works

115 verified catalyst event(s) dated in November 2026, each linked to its official source. Verified as of 2026-09-20.

Date	Event	Company	Drug	Official source & verification
2026-11 (month) in 1mo ESTIMATED	READOUT Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharma Phase 1/2 · Leukemia, Myeloid, Acute, Refractory AML	Aptose Biosciences Inc.	Tuspetinib, Venetoclax Oral Tablet, Azac	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Wa Phase 2 · Colorectal Cancer Stage II, Colorectal Cancer Stage III	BNTX BioNTech SE	RO7198457 intravenous (IV), Observationa	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency Phase 3 · Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency	MCUJF MEDICURE INC	Pyridoxal Phosphate	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-01 in 1mo ESTIMATED	READOUT Study of BBP-418 in Patients With LGMD2I Phase 2 · LGMD2I	ULS UL Solutions Inc.	BBP-418	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax Phase 2 · Chronic Lymphocytic Leukemia (CLL)	ABBV AbbVie Inc.	Venetoclax, Obinutuzumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Comb Phase 1/2 · Relapsed/Refractory Multiple Myeloma	ONC BeOne Medicines Ltd.	Sonrotoclax, Dexamethasone, Carfilzomib,	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participant Phase 1/2 · B-cell Malignancy, Marginal Zone Lymphoma	ONC BeOne Medicines Ltd.	Tacabrutideg	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patien Phase 3 · Gastro-enteropancreatic Neuroendocrine Tumor	Camurus AB	CAM2029, Octreotide LAR, Lanreotide ATG	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-01 in 1mo ESTIMATED	READOUT An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Sy Phase 3 · Lennox Gastaut Syndrome	Epygenix	Clemizole HCl	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age Phase 3 · Partial Epilepsy	SK Life Science, Inc.	Xcopri	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients Phase 3 · Multiple Sclerosis	IMUX IMMUNIC, INC.	IMU-838 tablets	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients W Phase 3 · Multiple Sclerosis, Relapsing-Remitting	IMUX IMMUNIC, INC.	IMU-838 tablets	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients W Phase 3 · Atherosclerotic Cardiovascular Disease	NAMS NewAmsterdam Pharma Co N.V.	Obicetrapib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Fo Phase 2 · High Grade Ovarian Cancer, Primary Peritoneal Cancer	ABBV AbbVie Inc.	Mirvetuximab soravtansine, Carboplatin	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients Phase 1/2 · Advanced Solid Tumor, Non Small Cell Lung Cancer	Anbogen Therapeutics, Inc.	ABT-101	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Ca Phase 1/2 · Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma	TYRA Tyra Biosciences, Inc.	TYRA-300	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Posit Phase 2 · Metastatic Breast Cancer	Stemline Therapeutics, Inc.	Elacestrant	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Can Phase 2 · Breast Neoplasms, Invasive Breast Cancer	ATOS ATOSSA THERAPEUTICS, INC.	(Z)-endoxifen, goserelin	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-01 in 1mo ESTIMATED	READOUT Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Pr Phase 3 · Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3	SRRK Scholar Rock Holding Corp	Apitegromab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT Gene Transfer Clinical Trial for Infantile and Late Infantile Krabbe Disease Tre Phase 1/2 · Krabbe Disease	Forge Biologics, Inc	FBX-101	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT Study to Evaluate Adverse Events, and Change in Disease Activity, When Intraveno Phase 2 · Hepatocellular Carcinoma	ABBV AbbVie Inc.	Budigalimab, Livmoniplimab, Lenvatinib,	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and B Phase 2 · Metastatic Colorectal Cancer, CRC	CRDF Cardiff Oncology, Inc.	Onvansertib, FOLFIRI, Bevacizumab, FOLFO	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT A Study of YL202 in Selected Patients With Advanced Solid Tumors Phase 2 · NSCLC, Breast Cancer	MediLink Therapeutics (Suzhou) Co.	YL202 should be intravenously infused	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Phase 3 · Non Muscle Invasive Bladder Cancer, Urologic Cancer	CGON CG Oncology, Inc.	Cretostimogene Grenadenorepvec, n-dodecy	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis Phase 2 · Pulmonary Sarcoidosis	Xentria, Inc.	XTMAB-16	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Hea Phase 2 · Cystic Fibrosis	ReCode Therapeutics	RCT2100, RCT2100, RCT2100, Ivacaftor	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatom Phase 2 · Dermatomyositis, Myositis	ARGX ARGENX SE	Empasiprubart IV	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Phase 2 · Progressive Supranuclear Palsy	Ferrer Internacional S.A.	FNP-223	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT A Study Evaluating APG777 in Atopic Dermatitis Phase 2 · Atopic Dermatitis	Apogee Therapeutics, Inc.	APG777	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels Phase 2 · Dyslipidemias	NAMS NewAmsterdam Pharma Co N.V.	obicetrapib 10 mg + obicetrapib/evolocum	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT Leniolisib for Immune Dysregulation in PIDs Phase 2 · Primary Immunodeficiency Disorders (PIDs)	Pharming Technologies B.V.	Leniolisib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-01 in 1mo ESTIMATED	READOUT First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor. Phase 1/2 · Solid Tumor	CRBP Corbus Pharmaceuticals Holdi	CRB-601 monoclonal antibody, Anti-PD-1 m	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutini Phase 2 · Chronic Lymphocytic Leukemia	ONC BeOne Medicines Ltd.	Sonrotoclax, Zanubrutinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Phase 3 · Obesity	LLY ELI LILLY & Co	Retatrutide, Tirzepatide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis Phase 2 · Idiopathic Pulmonary Fibrosis	Calluna Pharma AS	CAL101	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-01 in 1mo ESTIMATED	READOUT Tirbanibulin for Pediatric Warts Phase 4 · Warts Hand	The Skin Center Dermatology Group	Tirbanibulin ointment 1%	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With I Phase 2 · Idiopathic Hypersomnia	ALKS Alkermes plc.	ALKS 2680	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 Phase 2 · Generalized Anxiety Disorder (GAD)	ABBV AbbVie Inc.	ABBV-932, Antidepressant Therapy (ADT)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Phase 3 · Relapsing Multiple Sclerosis	Sandoz	CYB704, Ocrevus-EU, Ocrevus-US	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful O Phase 2 · Osteoarthritis (OA) of the Knee	PCRX Pacira BioSciences, Inc.	Enekinragene Inzadenovec (PCRX-201)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 D Phase 3 · Type 1 Diabetes, Obesity	LLY ELI LILLY & Co	Tirzepatide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-01 in 1mo ESTIMATED	READOUT A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Phase 3 · Bipolar-I Disorder With Mania or Mania With Mixed Features	BMY BRISTOL MYERS SQUIBB CO	KarXT	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Phase 3 · Type 1 Diabetes, Obesity	LLY ELI LILLY & Co	Tirzepatide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense Phase 2 · Hidradenitis Suppurativa (HS)	ZURA Zura Bio Ltd	Tibulizumab Dose A, Tibulizumab Dose B	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medic Phase 2 · Adjustment Disorder	Reunion Neuroscience Inc	RE104 for Injection	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Ye Phase 3 · Allergy, Peanut Allergy	DBVT DBV Technologies S.A.	DBV712 250 mcg	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Phase 2 · Gout, Gouty Arthritis	Arthrosi Therapeutics	AR882 75 mg, XOI Low Dose, XOI High Dose	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infec Phase 2 · Viral Hepatitis	VIR Vir Biotechnology, Inc.	Tobevibart, Elebsiran, Bulevirtide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated Wit Phase 2 · Diabetes Mellitus, Type 2	LLY ELI LILLY & Co	LY3938577, Degludec	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT A Study of LY4515100 in Participants With Pain Following Third Molar Removal Phase 2 · Acute Pain, Molar	LLY ELI LILLY & Co	LY4515100	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT To Assess the Efficacy of Two Brushing Regimens: in the Reduction of Established Phase 3 · Plaque, Dental, Gingivitis	CL COLGATE PALMOLIVE CO	Colgate SNaP Total 10/10, 1.5 Taurate, C	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-02 in 1mo ESTIMATED	READOUT A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer Phase 2 · Neoplasms, Rectal	GlaxoSmithKline	Dostarlimab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-02 in 1mo ESTIMATED	READOUT A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adult Phase 3 · Cutaneous Lupus Erythematosus	AZN ASTRAZENECA PLC	Anifrolumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-02 in 1mo ESTIMATED	READOUT A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti- Phase 2 · Melanoma	REGN REGENERON PHARMACEUTICALS, I	cemiplimab, Fixed Dose Combination (FDC)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-02 in 1mo ESTIMATED	READOUT A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Phase 3 · Bipolar Disorder Type I With Mania or Mania With Mixed Features	BMY BRISTOL MYERS SQUIBB CO	KarXT	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-03 in 1mo ESTIMATED	READOUT 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, Phase 3 · Chronic Spontaneous Urticaria	NVS NOVARTIS AG	LOU064 (blinded)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-05 in 2mo ESTIMATED	READOUT Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A o Phase 3 · Hemophilia	Genzyme, a Sanofi Company	Fitusiran	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-05 in 2mo ESTIMATED	READOUT Pediatric Long-Term Follow-up and Rollover Study Phase 4 · Diffuse Astrocytoma, Anaplastic Astrocytoma	NVS NOVARTIS AG	dabrafenib, trametinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-05 in 2mo ESTIMATED	READOUT Rollover Study to Provide Continued Treatment for Participants With B-Cell Malig Phase 2 · B-Cell Malignancies	INCY INCYTE CORP	Parsaclisib, parsaclisib + itacitinib, p	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-06 in 2mo ESTIMATED	READOUT Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Phase 2 · Hodgkin Lymphoma	Merck Sharp & Dohme LLC	pembrolizumab, doxorubicin, vinblastine,	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-06 in 2mo ESTIMATED	READOUT A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab ( Phase 3 · Chronic Rhinosinusitis With Nasal Polyps	SNY Sanofi	Itepekimab (SAR440340), Mometasone furoa	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-09 in 2mo ESTIMATED	READOUT A Platform Study of Novel Immunotherapy Combinations in Participants With Previo Phase 2 · Lung Cancer, Non-Small Cell	GlaxoSmithKline	Pembrolizumab, Dostarlimab, Belrestotug,	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-11 in 2mo ESTIMATED	READOUT Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuz Phase 3 · Breast Cancer; HER2-positive; Metastatic	AZN ASTRAZENECA PLC	Trastuzumab deruxtecan, Taxane, Pertuzum	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-11 in 2mo ESTIMATED	READOUT PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metast Phase 2 · Cervical Cancer, HPV-Related Carcinoma	PGEN PRECIGEN, INC.	PRGN-2009 plus Pembrolizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-13 in 2mo ESTIMATED	READOUT A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination Wi Phase 1/2 · Advanced Solid Tumors	REGN REGENERON PHARMACEUTICALS, I	REGN7075, Cemiplimab, Platinum-based dou	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-13 in 2mo ESTIMATED	READOUT A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compar Phase 3 · Breast Cancer	Hoffmann-La Roche	Inavolisib, Fulvestrant, Alpelisib, Bupr	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-13 in 2mo ESTIMATED	READOUT Study of Olatorepatide in Adult Participants Living With Overweight or Obesity i Phase 2 · Overweight or Obesity	REGN REGENERON PHARMACEUTICALS, I	Olatorepatide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-15 in 2mo ESTIMATED	READOUT Efficacy of M640 in Acute Lumbosacral Musculoskeletal Conditions. Phase 4 · Sciatica Acute, Lumbar Spinal Stenosis	Primus Pharmaceuticals	Metaxalone 640 mg Oral Tablet	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-15 in 2mo ESTIMATED	READOUT Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Gla Phase 2 · Glaucoma, Open-Angle, Ocular Hypertension	PolyActiva Pty Ltd	PA5108 Ocular Implant low dose, PA5108 O	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-16 in 2mo ESTIMATED	READOUT A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Gener Phase 2/3 · Generalized Myasthenia Gravis	UCB Biopharma SRL	Zilucoplan	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-17 in 2mo ESTIMATED	READOUT AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 Phase 2 · Gastric Cancer, Gastroesophageal Junction Cancer	AZN ASTRAZENECA PLC	AZD0901, 5-Fluorouracil, Leucovorin, l-l	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-17 in 2mo ESTIMATED	READOUT A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemo Phase 4 · Haemophilia A (Moderate or Severe), Hemophilia, Classic	Swedish Orphan Biovitrum	Efanesoctocog alfa	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-18 in 2mo ESTIMATED	READOUT Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polym Phase 2/3 · Small Cell Lung Cancer	Han Xu, M.D., Ph.D., FAPCR, Medica	ETOPOSIDE - Usual, ETOPOSIDE - Study	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-18 in 2mo ESTIMATED	READOUT Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucl Phase 2/3 · Prostate Cancer	Han Xu, M.D., Ph.D., FAPCR, Sponso	Abiraterone - Usual, Abiraterone - Study	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-18 in 2mo ESTIMATED	READOUT A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Ac Phase 3 · Sjögren's Syndrome	BMY BRISTOL MYERS SQUIBB CO	Deucravacitinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-18 in 2mo ESTIMATED	READOUT Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymo Phase 2/3 · ALK-Positive Non-Small Cell Lung Cancer (NSCLC)	Han Xu, M.D., Ph.D., FAPCR, Medica	ALECENSA - alectinib hydrochloride capsu	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-18 in 2mo ESTIMATED	READOUT A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular D Phase 2 · Duchenne Muscular Dystrophy	Hoffmann-La Roche	Satralizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-18 in 2mo ESTIMATED	READOUT An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer Phase 2 · Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)	ToLymph Inc.	SMS001	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-18 in 2mo ESTIMATED	READOUT Efficacy and Safety of NVX-CoV2705 Phase 4 · COVID-19, Sars-CoV-2 Infection	NVAX NOVAVAX INC	NVX-CoV2705	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-19 in 2mo ESTIMATED	READOUT A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participant Phase 2 · Alzheimer's Disease	Hoffmann-La Roche	RO7269162	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-19 in 2mo ESTIMATED	READOUT A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatiti Phase 2 · Dermatitis, Atopic	Janssen Research & Development, LL	JNJ-95597528	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-19 in 2mo CONFIRMED	ADCOM Microbiology Devices Panel of the Medical Devices Advisory Committee Microbiology Devices Panel of the Medical Devices Advisory Committee	Microbiology Devices Panel of the	FDORA	Federal Register (FDA notice) ↗ ✓ Source-checked 2026-09-20 Scheduled FDA meeting date
2026-11-20 in 2mo ESTIMATED	READOUT Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With Phase 3 · Endometrial Neoplasms	Merck Sharp & Dohme LLC	Pembrolizumab, Carboplatin, Paclitaxel,	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-20 in 2mo ESTIMATED	READOUT A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participant Phase 2 · Moderate to Severe Asthma	INCY INCYTE CORP	povorcitinib, ICS-LABA	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-20 in 2mo ESTIMATED	READOUT Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-admi Phase 2 · Obesity	SKYE Skye Bioscience, Inc.	Nimacimab injection, Nimacimab placebo i	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-23 in 2mo ESTIMATED	READOUT A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) V Phase 2 · Neoplasms, Colon	GlaxoSmithKline	Dostarlimab, CAPEOX	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-23 in 2mo ESTIMATED	READOUT A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to He Phase 3 · Chickenpox	GlaxoSmithKline	Investigational varicella vaccine, Marke	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-24 in 2mo ESTIMATED	READOUT Study of AZD0754 in Participants With Metastatic Prostate Cancer Phase 1/2 · Metastatic Prostate Cancer	AZN ASTRAZENECA PLC	AZD0754, AZD2287	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-24 in 2mo ESTIMATED	READOUT A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer Phase 3 · Alzheimer Disease	Karuna Therapeutics, Inc., a Brist	KarXT	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-24 in 2mo ESTIMATED	READOUT A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart F Phase 2 · Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction	TECX Tectonic Therapeutic, Inc.	TX000045- Dose A, TX000045- Dose B	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-26 in 2mo ESTIMATED	READOUT A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Phase 3 · Neoplasms	Tesaro, Inc.	Dostarlimab, Carboplatin, Paclitaxel, Ni	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-27 in 2mo ESTIMATED	READOUT A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in Phase 2 · Type 2 Diabetes Mellitus	Hoffmann-La Roche	RO7795081, Semaglutide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-28 in 2mo ESTIMATED	READOUT A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Phase 2 · Parkinson's Disease (PD)	TrueBinding, Inc.	TB006	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-29 in 2mo ESTIMATED	READOUT A Study to Learn About the Study Medicine Called Rimegepant in Women When Used f Phase 3 · Menstrual Migraine	PFE PFIZER INC	Rimegepant, Rimegepant	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-30 in 2mo ESTIMATED	READOUT Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutat Phase 1/2 · Glioblastoma Multiforme	NTHI NEONC TECHNOLOGIES HOLDINGS,	Perillyl alcohol	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-30 in 2mo ESTIMATED	READOUT A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety Phase 1/2 · Multiple Myeloma	Celgene	CC-92480, Bortezomib, Dexamethasone, Dar	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-30 in 2mo ESTIMATED	READOUT A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Phase 2 · Non-small Cell Lung Cancer	Genentech, Inc.	Alectinib, Entrectinib, Vemurafenib, Cob	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-30 in 2mo ESTIMATED	READOUT A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MT Phase 1/2 · Advanced MTAP-null Solid Tumors	AMGN AMGEN INC	Anvumetostat, Docetaxel, Comparator Anvu	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-30 in 2mo ESTIMATED	READOUT A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage D Phase 1/2 · Glycogen Storage Disease	ModernaTX, Inc.	mRNA-3745	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-30 in 2mo ESTIMATED	READOUT Pediatric Patients Aged 4 to 11 Years With APDS Phase 3 · APDS	Pharming Technologies B.V.	Leniolisib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-30 in 2mo ESTIMATED	READOUT A Study to Evaluate Efficacy and Safety of AVTX-803 in Patients With Leukocyte A Phase 3 · Leukocyte Adhesion Deficiency	AUG Therapeutics	AVTX-803 (L-Fucose)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-30 in 2mo ESTIMATED	READOUT ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC Phase 1/2 · Metastatic Castration-resistant Prostate Cancer	OncoC4, Inc.	ONC-392 low, ONC-392 high, lutetium Lu 1	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-30 in 2mo ESTIMATED	READOUT AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Phase 1/2 · Mesial Temporal Lobe Epilepsy	UniQure Biopharma B.V.	AAV9-hSyn1-miGRIK2	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-30 in 2mo ESTIMATED	READOUT Suprachoroidal Administration in Subjects With Metastases to the Choroid Phase 2 · Eye Cancer, Primary Cancer	AURA Aura Biosciences, Inc.	AU-011, SCS Microinjector, Laser	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-30 in 2mo ESTIMATED	READOUT A Study of TAK-360 in Adults With Idiopathic Hypersomnia Phase 2 · Idiopathic Hypersomnia	TAK TAKEDA PHARMACEUTICAL CO LTD	TAK-360	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-30 in 2mo ESTIMATED	READOUT A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) Phase 2 · Narcolepsy Type 2	TAK TAKEDA PHARMACEUTICAL CO LTD	TAK-360	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-30 in 2mo ESTIMATED	READOUT A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metast Phase 3 · Breast Cancer	InventisBio Co., Ltd	D-0502, Fulvestrant	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-30 in 2mo ESTIMATED	READOUT A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12 Phase 1/2 · KRAS G12D Mutation, Advanced Solid Cancer	ARVN ARVINAS, INC.	ARV-806	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-30 in 2mo ESTIMATED	READOUT Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production C Phase 2 · Monkeypox (Mpox)	Bavarian Nordic	Jynneos, MVA-BN (Quail)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-30 in 2mo ESTIMATED	READOUT Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Pha Phase 3 · Immune Thrombocytopenia	SNY Sanofi	rilzabrutinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-30 in 2mo ESTIMATED	READOUT Phase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis K Phase 3 · Osteoarthritis Knee Pain	Saol Therapeutics Inc	SL1002, Normal Saline	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-30 in 2mo ESTIMATED	READOUT Investigating Ovulation Inhibition for Use as a Contraceptive Phase 2 · Contraception	Mylan Pharmaceuticals Inc	MR-130A-01 contraceptive transdermal pat	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-30 in 2mo ESTIMATED	READOUT A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in P Phase 2 · Obesity, Overweight	Verdiva Bio Dev Limited	VRB-101	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-30 in 2mo ESTIMATED	READOUT A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE Phase 2 · Obesity and Cardiovascular Risk	BIOA BioAge Labs, Inc.	Oral BGE-102, Oral Placebo Matching BGE-	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-30 in 2mo ESTIMATED	READOUT Study to Assess Safety and Tolerability of KarXT With Administration of Antiemet Phase 4 · Healthy Volunteers	Karuna Therapeutics, Inc., a Brist	KarXT, Trimethobenzamide, Ondansetron, M	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change